131 related articles for article (PubMed ID: 17304504)
21. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin.
Schultze K; Böck B; Eckert A; Oevermann L; Ramacher D; Wiestler O; Roth W
Apoptosis; 2006 Sep; 11(9):1503-12. PubMed ID: 16820965
[TBL] [Abstract][Full Text] [Related]
22. Ran GTPase protein promotes human pancreatic cancer proliferation by deregulating the expression of Survivin and cell cycle proteins.
Deng L; Lu Y; Zhao X; Sun Y; Shi Y; Fan H; Liu C; Zhou J; Nie Y; Wu K; Fan D; Guo X
Biochem Biophys Res Commun; 2013 Oct; 440(2):322-9. PubMed ID: 24076388
[TBL] [Abstract][Full Text] [Related]
23. Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin.
Yoon MJ; Park SS; Kang YJ; Kim IY; Lee JA; Lee JS; Kim EG; Lee CW; Choi KS
Carcinogenesis; 2012 Mar; 33(3):492-500. PubMed ID: 22159225
[TBL] [Abstract][Full Text] [Related]
24. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
25. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B; Shi ZL; Feng J; Tao HM
Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766
[TBL] [Abstract][Full Text] [Related]
26. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
[TBL] [Abstract][Full Text] [Related]
27. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.
Kanzaki H; Ohtaki A; Merchant FK; Greene MI; Murali R
Exp Mol Pathol; 2013 Apr; 94(2):372-9. PubMed ID: 23219833
[TBL] [Abstract][Full Text] [Related]
28. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21.
Mortoglou M; Miralles F; Mould RR; Sengupta D; Uysal-Onganer P
Eur J Cell Biol; 2023 Jun; 102(2):151318. PubMed ID: 37105116
[TBL] [Abstract][Full Text] [Related]
30. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
[TBL] [Abstract][Full Text] [Related]
32. IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells.
Büneker CK; Yu R; Deedigan L; Mohr A; Zwacka RM
Cancer Lett; 2012 Mar; 316(2):168-77. PubMed ID: 22104728
[TBL] [Abstract][Full Text] [Related]
33. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells.
Vogler M; Dürr K; Jovanovic M; Debatin KM; Fulda S
Oncogene; 2007 Jan; 26(2):248-57. PubMed ID: 16832350
[TBL] [Abstract][Full Text] [Related]
34. Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.
Son YG; Kim EH; Kim JY; Kim SU; Kwon TK; Yoon AR; Yun CO; Choi KS
Cancer Res; 2007 Sep; 67(17):8274-84. PubMed ID: 17804742
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
[TBL] [Abstract][Full Text] [Related]
36. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma.
Zhang B; Li D; Jin X; Zhang K
Int J Biochem Cell Biol; 2020 Nov; 128():105859. PubMed ID: 32987196
[TBL] [Abstract][Full Text] [Related]
37. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity.
Calbó J; Serna C; Garriga J; Graña X; Mazo A
Cell Death Differ; 2004 Oct; 11(10):1055-65. PubMed ID: 15309028
[TBL] [Abstract][Full Text] [Related]
38. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death.
Ruff JP; Kretz AL; Kornmann M; Henne-Bruns D; Lemke J; Traub B
Anticancer Res; 2021 Dec; 41(12):5973-5985. PubMed ID: 34848451
[TBL] [Abstract][Full Text] [Related]
39. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
Kim EH; Kim HS; Kim SU; Noh EJ; Lee JS; Choi KS
Oncogene; 2005 Oct; 24(46):6877-89. PubMed ID: 16007142
[TBL] [Abstract][Full Text] [Related]
40. Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma.
Zhou Y; Shen JK; Yu Z; Hornicek FJ; Kan Q; Duan Z
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1573-1582. PubMed ID: 29452249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
